Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Concordia Healthcare Group
Concordia Healthcare Group
Activities:
Medical Devices
Pharmaceutical
X
LinkedIn
Trending Articles
Optimising RNA production for faster and cheaper pharmaceutical manufacturing
RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Regulatory
Drug company accused of abusing its position to overcharge the NHS
The Competition and Markets Authority (CMA) has provisionally found that Concordia abused its dominant position to overcharge the NHS
Finance
Concordia Healthcare to purchase AMCo
UK-based global pharmaceutical company, AMCo, is to be bought by the Canadian healthcare business Concordia
Finance
Concordia Healthcare to buy certain assets of Covis Pharma for US$1.2bn
The all-cash deal will be financed with a mix of term loans, bonds and equity
Subscribe now